An International Multicentre Parallel-group Randomised Double-blind Placebo-controlled Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)

Brief description of study

AstraZeneca is doing this research to find out if the new medication called dapagliflozin will work and be safe for the treatment of heart failure. Dapagliflozin (ForxigaTM/FarxigaTM) is an approved drug to treat type 2 diabetic patients worldwide. Previous research studies show that dapagliflozin might also have beneficial effects on heart failure regardless of your diabetes status. This research study (referred as DETERMINE-reduced) will help to answer the question whether dapagliflozin can increase exercise capacity in patients with heart failure. It will be measured as a change in the distance the patient can walk in a 6-minute period over the course of study. Dapagliflozin will be compared with placebo, an inactive and identical-looking medicine. It will not interfere with your current treatment for heart failure.


Clinical Study Identifier: s18-01901
ClinicalTrials.gov Identifier: NCT03877237
Principal Investigator: Cezar S Staniloae
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.